Novartis is cutting a sizable check to tap China's mRNA know‑how. Under the Abogen deal, Novartis is putting down $575 million upfront to secure worldwide rights to an mRNA therapy, and could owe up to $7.2 billion more if milestones are achieved. Novartis also secured an exclusive option to license additional assets built on Abogen's RNA platform.
Instead of buying companies outright, Western pharmas are increasingly opting for licenses to access Chinese innovation. Ruchun Ji, a partner at Sidley, told CNBC that this approach lowers risk because a license can be terminated if a drug underwhelms or priorities shift. For Chinese biotechs, those upfront checks and milestone payments bring in funding while they continue advancing medicines in their home market. "The speed of innovation, speed of clinical trials in China is really, really fast," Ji said, crediting reforms from China's drug regulator NMPA, saying it has "totally overhauled the systems over the last couple of years." She added that the return of China's overseas‑trained scientists, paired with faster and cheaper early development, has produced the kind of data that draws the world's biggest drugmakers.
This isn't a one off. Earlier this week, Novo revealed it had struck an exclusive license with Hengrui Pharma covering an early‑stage oral GLP‑1/GIP taken once weekly, with total potential value of $2.6 billion. Facing stiffening anti‑obesity rivalry, Novo's stock has slumped over the past two years, increasing pressure on the company to identify a follow‑on to its semaglutide lineup, which includes Wegovy and Ozempic.
In mid September, GSK said it would buy a hematology cancer asset from China's Chimagen Biosciences for as much as $750 million. Chris Sheldon, GSK's head of business development, told investors in London last month that while the company does not target specific geographies, the proportion of fresh biotech innovation coming from China is rising quickly.
Understanding what moved a market beats knowing that it moved. Get the free Market Briefs daily newsletter and follow the drivers.
ING forecasts that by 2026 China will make up roughly one‑third of new molecules in worldwide pipelines, compared with 4% in 2014. The bank further anticipates Chinese biotech out‑licensing deal values will exceed $250 billion in 2026 as international demand increases.
Chinese developed drugs are increasingly being pulled into Big Pharma programs. Early Friday, AstraZeneca said it formed a collaboration with Summit Therapeutics to evaluate its oncology drugs. Working alongside Daiichi Sankyo, the parties plan to study AstraZeneca's cancer therapy Datroway in combination with Summit's ivonescimab - first developed by China's Akeso and later licensed to Summit - across multiple tumour types.
AstraZeneca plans to put $15 billion into China by 2030 to grow its manufacturing and R&D footprint, and in the past few months has inked multiple China-focused licensing agreements each carrying potential deal sizes exceeding $1 billion.
The playbook is taking shape - big upfronts, hefty milestones, and global rights without full takeovers. If China keeps supplying a larger slice of pharma's pipeline, expect more of these cross border tie ups and more capital moving with them. That changes where future drug wins and late stage misses might show up in a portfolio.
A few minutes a day is enough to stay genuinely informed about your money. Join Market Briefs free and start tomorrow.
